Novartis Scemblix® granted FDA Priority Review for the ...

July 29, 2024

Scemblix® (asciminib) granted FDA Priority Review for Ph+ CML-CP treatment, showing superior molecular response and safety over standard therapies. ASC4FIRST Phase III study highlights its efficacy and tolerability, marking a significant advancement in CML care.

Related Clinical Trials

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP.

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

Reference News

novartis.com

Novartis Scemblix® granted FDA Priority Review for the ...